Most Viewed Articles
Articles | Fulltext downloads | PDF downloads | Total downloads |
---|---|---|---|
Review ArticleAntibody-drug conjugate review in breast cancer: A targeted approachFull text![]() ![]() ![]() Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_30_2024 |
12,716 | 36,823 | 49,539 |
Short CommunicationOutcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in BangladeshFull text![]() ![]() ![]() Volume 6 | Issue 1 | January-April 2021DOI: 10.25259/IJMIO_30_2020 |
45,605 | 3,699 | 49,304 |
Short CommunicationDriver mutations in oncogenesisFull text![]() ![]() ![]() Volume 6 | Issue 2 | May-August 2021DOI: 10.25259/IJMIO_26_2020 |
39,377 | 4,974 | 44,351 |
Review ArticleGenetic diversity and variation in chronic myeloid leukemia patients of Indian origin- Implications for treatment response and prognosisFull text![]() ![]() ![]() Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_11_2024 |
12,222 | 30,934 | 43,156 |
Case ReportCase report – Muir–Torre syndrome – A skin-deep manifestation of underlying malignancyFull text![]() ![]() ![]() Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_26_2024 |
12,059 | 26,128 | 38,187 |
Review ArticleMini review: Molecular pathology of personalized medicine in cancer susceptibility syndromesFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_12_2023 |
28,710 | 3,228 | 31,938 |
Review ArticleEmerging strategies in cancer immunotherapy: Expanding horizons and future perspectivesFull text![]() ![]() ![]() Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_24_2024 |
13,451 | 17,696 | 31,147 |
EditorialChallenging conventional wisdom in molecular oncology: New perspectivesFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_20_2023 |
27,129 | 3,102 | 30,231 |
Original ArticleOutcomes with atezolizumab and bevacizumab in hepatocellular carcinoma – Real-world data from IndiaFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_15_2023 |
27,018 | 2,952 | 29,970 |
Case ReportLong-term efficacy of osimertinib in de novo exon 19 deletion with T790M in an epidermal growth factor receptor mutated lung cancer patient in IndiaFull text![]() ![]() ![]() Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_16_2023 |
24,477 | 3,102 | 27,579 |
Case ReportBreast carcinoma disguised as systemic sclerosis: A case report of unusual paraneoplastic syndromeFull text![]() ![]() ![]() Volume 10 | Issue 1 | January-April 2025DOI: 10.25259/IJMIO_4_2024 |
8,424 | 18,600 | 27,024 |
Review ArticleMolecular oncology and the role of artificial intelligence in advancing cancer treatmentFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_17_2023 |
23,048 | 2,278 | 25,326 |
Original ArticleSpectrum of lymphomas in IndiaFull text![]() ![]() ![]() Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_18_2023 |
19,268 | 2,953 | 22,221 |
EditorialCrucial crossroads: Making the right choice for first-line therapy in advanced urothelial cancerFull text![]() ![]() ![]() Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_2_2024 |
18,206 | 3,712 | 21,918 |
Review ArticleUse of five-day chronomodulated prescription of palbociclib as myelopreservation drug along with Topotecan in recurrent extensive stage small cell lung carcinoma – A perspective articleFull text![]() ![]() ![]() Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_3_2024 |
18,363 | 3,420 | 21,783 |
NewsEditorial board tribute to Dr. Amit VermaFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021 |
16,621 | 4,040 | 20,661 |
Review ArticleHigh-dose nicotinamide, a histone deacetylase inhibitor (Sirtuin-1), can prevent emergence of treatment resistance in chronic myeloid leukemia – A perspectiveFull text![]() ![]() ![]() Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_1_2024 |
17,145 | 3,117 | 20,262 |
Review ArticleCan CDK 4/6 inhibitors be used in patients with visceral crises? Deviating from conventional teachingFull text![]() ![]() ![]() Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_8_2022 |
14,152 | 6,049 | 20,201 |
Case ReportClinical experience of total body irradiation performed on Halcyon™ for a patient diagnosed with acute myeloid leukemiaFull text![]() ![]() ![]() Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_5_2022 |
13,197 | 6,710 | 19,907 |
Review ArticleUnderstanding immunotherapy and CAR-T-cells: A narrative reviewFull text![]() ![]() ![]() Volume 9 | Issue 1 | January-April 2024DOI: 10.25259/IJMIO_22_2023 |
17,075 | 2,666 | 19,741 |
Case ReportSquamous cell carcinoma of lung presenting as “Sunray sign” in chest radiographFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_6_2023 |
15,664 | 2,990 | 18,654 |
Review ArticleIs continuous infusion of high-dose ifosfamide, a safe option? Drug reviewFull text![]() ![]() ![]() Volume 5 | Issue 2 | May-August 2020DOI: 10.25259/IJMIO_21_2019 |
13,595 | 4,655 | 18,250 |
Cardio Oncology with ACOSIbrutinib and atrial fibrillation as cardiotoxicity – A new safety warning that impacts overall survivalFull text![]() ![]() ![]() Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_1_2022 |
12,746 | 5,300 | 18,046 |
Case ReportHyperthermic intraperitoneal chemotherapy in primary peritoneal cancer: Our experience in a young maleFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_16_2021 |
14,689 | 3,056 | 17,745 |
Review ArticleSignaling pathways in pancreatic ductile adenocarcinoma and potential therapeutic targetsFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_29_2022 |
14,711 | 2,951 | 17,662 |
New Drug UpdateAmlodipine-induced inhibition of NFAT-2 nuclear translocation and its utility as an additive to immune checkpoint inhibitorFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_13_2021 |
14,547 | 2,890 | 17,437 |
Review ArticleCombination of PARPi and anti-PD-L1 therapies in ovarian cancerFull text![]() ![]() ![]() Volume 8 | Issue 2 | May-August 2023DOI: 10.25259/IJMIO_28_2022 |
15,081 | 2,031 | 17,112 |
Review ArticlePotential therapeutic molecular targets for better outcomes for patients with lung cancerFull text![]() ![]() ![]() Volume 8 | Issue 2 | May-August 2023DOI: 10.25259/IJMIO_27_2022 |
15,388 | 1,681 | 17,069 |
Review ArticleImmune dynamics of SARS-CoV-2 virus evolutionFull text![]() ![]() ![]() Volume 7 | Issue 1 | January-April 2022DOI: 10.25259/IJMIO_26_2021 |
11,510 | 5,483 | 16,993 |
Original ArticleIncorporation of immunohistochemistry in the assessment of survival and prognosis of endometrial cancers: Are we ready for the change?Full text![]() ![]() ![]() Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_2_2022 |
11,861 | 5,056 | 16,917 |
Review ArticleAdvances in immunotherapy for metastatic esophageal cancerFull text![]() ![]() ![]() Volume 7 | Issue 3 | September-December 2022DOI: 10.25259/IJMIO_14_2022 |
11,132 | 5,170 | 16,302 |
Brief CommentaryBreast cancer prognostic tools: A promising Indian optionFull text![]() ![]() ![]() Volume 5 | Issue 2 | May-August 2020DOI: 10.25259/IJMIO_15_2020 |
10,527 | 5,654 | 16,181 |
Review ArticleImmuno-oncological era of breast cancer: A progressive path to better treatmentFull text![]() ![]() ![]() Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_3_2022 |
9,824 | 6,213 | 16,037 |
Case SeriesDual driver in non-small cell lung carcinoma – therapeutic dilemmaFull text![]() ![]() ![]() Volume 7 | Issue 1 | January-April 2022DOI: 10.25259/IJMIO_22_2021 |
12,796 | 2,965 | 15,761 |
Review ArticleImmuno-oncology of differentiated thyroid cancerFull text![]() ![]() ![]() Volume 6 | Issue 2 | May-August 2021DOI: 10.25259/IJMIO_36_2020 |
11,324 | 4,304 | 15,628 |
Review ArticleA compendium of population wide DNA methylation profile for oral cancer in IndiaFull text![]() ![]() ![]() Volume 6 | Issue 2 | May-August 2021DOI: 10.25259/IJMIO_2_2021 |
10,761 | 4,646 | 15,407 |
Case ReportL1CAM expressing, ZFTA:: NCOA1 fusion-positive supratentorial ependymoma: A case reportFull text![]() ![]() ![]() Volume 8 | Issue 3 | September-December 2023DOI: 10.25259/IJMIO_11_2023 |
13,212 | 2,182 | 15,394 |
Review ArticleThe evolving role of precision medicine in the management of advanced sarcomas – A mini reviewFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_6_2021 |
12,123 | 3,209 | 15,332 |
Case ReportComplete metabolic response with letrozole and palbociclib in advanced breast cancerFull text![]() ![]() ![]() Volume 4 | Issue 3 | September-December 2019DOI: 10.25259/IJMIO_2_2019 |
9,271 | 5,905 | 15,176 |
Review ArticleThe Cancer Genomic Atlas – “TO CONQUER CANCER”Full text![]() ![]() ![]() Volume 6 | Issue 2 | May-August 2021DOI: 10.25259/IJMIO_28_2020 |
10,791 | 4,332 | 15,123 |
Review ArticlePost-chemotherapy maintenance treatment by nicotinamide riboside, a poly ADP ribose polymerase 1 inhibitor, in BRCA mutated advanced ovarian cancer – A perspectiveFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_12_2021 |
11,589 | 3,376 | 14,965 |
Review ArticleEndocrine toxicity of cancer immunotherapyFull text![]() ![]() ![]() Volume 9 | Issue 2 | May-August 2024DOI: 10.25259/IJMIO_19_2024 |
13,623 | 1,334 | 14,957 |
Review ArticleMolecular genetics changes in gallbladder carcinomaFull text![]() ![]() ![]() Volume 5 | Issue 2 | May-August 2020DOI: 10.25259/IJMIO_19_2019 |
9,737 | 5,134 | 14,871 |
Case ReportUnusual presentation of an Epstein barr virus-negative extranodal natural killer/T cell lymphoma: A diagnostic dilemmaFull text![]() ![]() ![]() Volume 7 | Issue 1 | January-April 2022DOI: 10.25259/IJMIO_18_2021 |
11,647 | 3,095 | 14,742 |
Review ArticlePatient perspectives on living with chronic myeloid leukemia in India: Quality of life, psychosocial support, and stigmaFull text![]() ![]() ![]() Volume 9 | Issue 3 | September-December 2024DOI: 10.25259/IJMIO_17_2024 |
13,902 | 762 | 14,664 |
Case ReportRedefining the treatment of metastatic uveal melanoma with immunotherapy – A case reportFull text![]() ![]() ![]() Volume 7 | Issue 2 | May – August 2022DOI: 10.25259/IJMIO_11_2022 |
11,331 | 3,225 | 14,556 |
EditorialNanobytesFull text![]() ![]() ![]() Volume 4 | Issue 3 | September-December 2019DOI: 10.25259/IJMIO_7_2019 |
6,812 | 7,567 | 14,379 |
Brief CommentaryERBB and FGFR2 pathway inhibition in biliary tract cancers – Dawn of a new beginningFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_10_2021 |
10,983 | 3,275 | 14,258 |
Brief CommentaryBioactive lipid: A novel diagnostic approach for retinoblastoma in clinical managementFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_7_2021 |
10,703 | 3,435 | 14,138 |
Conference Review6th Molecular Oncology Society Conference: Improving patient survival by molecularly targeted therapiesFull text![]() ![]() ![]() Volume 6 | Issue 3 | September-December 2021DOI: 10.25259/IJMIO_20_2021 |
11,551 | 2,577 | 14,128 |